On Wednesday, October 22nd, BIOMERIEUX stock rose by 3.27%, closing at €113.70, despite a generally unfavorable market environment, with the CAC 40 index falling by 0.63%. However, trading volume remained low, with only 0.13% of the capital changing hands during the session.
The stock of the medical technology specialist opened strong, gaining €3.50 from the previous closing price of €110.10. This daily performance extends a positive trend observed over the past week, with the stock now showing a weekly gain of 4.79%. Over the year, BIOMERIEUX's stock has increased by 8.60%, slightly underperforming the CAC 40's gain of 8.90% for the same period. Capital turnover remains particularly low at only 0.13% during the session, indicating a cautious approach by market participants despite the price rebound. Over three months, the stock still shows a decline of 3.97%, reflecting a period of consolidation after reaching highs earlier in the year. The stock is now trading close to its major resistance level at €116.60, with support at €108.50.
Technical Analysis Overview
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, BIOMERIEUX's stock is trading below its key moving averages. Specifically, it is below the 50-day moving average of €116.56 and the 200-day moving average of €117.15. The RSI indicator is at 35, a relatively low level indicating potential exhaustion of the recent downward trend. The MACD shows a negative setup with a main line at -1.39 and a signal line at -1.17, with the histogram at -0.22. Bollinger Bands frame the stock's price movement between €107.73 for the lower band and €117.54 for the upper band. The stochastic relative strength index suggests a sell signal, while the CMF indicator is slightly positive at 0.07. The one-month volatility is at 6.82, and the stock's beta of -0.05 indicates a very low correlation with overall market movements.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
